Thanks for emailing that article!
Our Mission is to cure glaucoma and restore vision through innovative research.
In 2020, scientists exploring the biological building blocks of vision uncovered special retinal ganglion cells that play a role in blood flow and pressure in the eye. Their discovery may lead to the design of artificial cells that, transplanted into eyes damaged by glaucoma, could restore vision.
This is just one of many innovations, made possible through your generosity to Glaucoma Research Foundation, that bring us closer to a future free from glaucoma.
Thank You! What an amazing year. A year of resilience and inspiration, incredible progress and heartbreaking loss. We are so grateful to our friends and supporters who have helped to make this tumultuous year a year of great success for Glaucoma Research Foundation. By any measure, 2020 has shown us the resilience of the scientists we fund and the loyalty of our many donors. 2020 has taught us to be flexible and has helped us reinvent the way we work and communicate with patients, families, doctors and the public. Dealing with COVID has been a challenge for us all, and together we are stronger and more resilient as a result.
Catalyst for a Cure scientists inspired us with their excellent progress this year. During the time their labs were briefly closed due to the pandemic, they were able to continue their work by pivoting to a virtual platform. The team switched from lab research to studying and collaborating about the experiments they would do when they were able to return to their labs in June. Two clear paths to vision restoration were identified: protecting and restoring the retinal nerve cells and replacing and reconnecting lost nerve cells. Experiments are now underway to test their ideas.
Inspired by the research progress and the most successful Glaucoma 360 yet, our friends and donors helped us not only reach, but surpass our $25 million Cure is in Sight Campaign which concluded on June 30. The largest fund-raising effort in our 42-year history enables the Catalyst for a Cure Vision Restoration collaboration, one-year Shaffer Grant pilot research projects for new investigators and ideas in glaucoma, and education and awareness programs like our many webinars.
With vaccines and treatments becoming available, we all look forward to more in person events in the future while continuing our webinars and outreach to our new global friends.
Thomas M. Brunner
President and CEO
Andrew G. Iwach, MD